These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22229963)

  • 21. The effect of the medicine administration route on health-related quality of life: Results from a time trade-off survey in patients with bipolar disorder or schizophrenia in 2 Nordic countries.
    Jørgensen TR; Emborg C; Dahlen K; Bøgelund M; Carlborg A
    BMC Psychiatry; 2016 Jul; 16():244. PubMed ID: 27421880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
    Brook S
    J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New medical approach to out-of-hospital treatment of psychomotor agitation in psychiatric patients: a report of 14 cases].
    Cester-Martínez A; Cortés-Ramas JA; Borraz-Clares D; Pellicer-Gayarre M
    Emergencias; 2017 Jun; 29(3):182-184. PubMed ID: 28825239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens.
    Spyker DA; Riesenberg RA; Cassella JV
    J Clin Pharmacol; 2015 Sep; 55(9):985-94. PubMed ID: 25808074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department.
    Cole JB; Klein LR; Mullinax SZ; Nordstrom KD; Driver BE; Wilson MP
    Acad Emerg Med; 2019 May; 26(5):559-566. PubMed ID: 30548977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Inhaled Loxapine in Dual-Diagnosis Patients: A Case Series.
    Roncero C; Ros-Cucurull E; Grau-López L; Fadeuilhe C; Casas M
    Clin Neuropharmacol; 2016; 39(4):206-9. PubMed ID: 27015036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.
    Gross N; Greos LS; Meltzer EO; Spangenthal S; Fishman RS; Spyker DA; Cassella JV
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):478-87. PubMed ID: 24745666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting.
    Zeller SL; Citrome L
    West J Emerg Med; 2016 Mar; 17(2):165-72. PubMed ID: 26973742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled Loxapine for Agitation in Intoxicated Patients: A Case Series.
    Roncero C; Ros-Cucurull E; Palma-Álvarez RF; Abad AC; Fadeuilhe C; Casas M; Grau-López L
    Clin Neuropharmacol; 2017; 40(6):281-285. PubMed ID: 29045249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled Loxapine for Acute Treatment of Agitation in Patients With Borderline Personality Disorder: A Case Series.
    Kahl KG; Negt P; Wollmer A; Jung S; Kruger TH
    J Clin Psychopharmacol; 2015 Dec; 35(6):741-3. PubMed ID: 26448403
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhaled Loxapine for ECT Pretreatment for Agitation.
    Jaffe R; Siniscalchi M; Cruz-Luna N; Cosgrove D
    J ECT; 2016 Jun; 32(2):146. PubMed ID: 26439438
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical perspectives on atypical antipsychotics for treatment of agitation.
    Caine ED
    J Clin Psychiatry; 2006; 67 Suppl 10():22-31. PubMed ID: 16965192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient preferences for medicine administration for acute agitation: results from an internet-based survey of patients diagnosed with bipolar disorder or schizophrenia in two Nordic countries.
    Jørgensen TR; Emborg C; Dahlen K; Bøgelund M; Carlborg A
    Psychol Health Med; 2018 Jan; 23(1):30-38. PubMed ID: 28475360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New formulations of olanzapine in the treatment of acute agitation].
    Bartkó G
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):171-8. PubMed ID: 17211052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine?
    Meltzer HY; Jayathilake K
    J Clin Psychiatry; 1999; 60 Suppl 10():47-51. PubMed ID: 10340687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond.
    Nuss P; Corruble E; Baloche E; P Garay R; Llorca PM
    Expert Rev Neurother; 2022 Aug; 22(8):639-653. PubMed ID: 35913401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhaled loxapine for agitation in patients with personality disorder: an initial approach.
    Patrizi B; Navarro-Haro MV; Gasol M
    Eur Neuropsychopharmacol; 2019 Jan; 29(1):122-126. PubMed ID: 30497838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic.
    Ereshefsky L
    J Clin Psychiatry; 1999; 60 Suppl 10():20-30. PubMed ID: 10340684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid tranquilization: a comparison of thiothixene with loxapine.
    Dubin WR; Weiss KJ
    J Clin Psychiatry; 1986 Jun; 47(6):294-7. PubMed ID: 3711026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.